Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
20 Sep 2020
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Treating follicular lymphoma boosts survival in older adults

11 Jan 2020
Doctors are most likely to miss difficult-to-diagnose conditions such as myeloma, lymphoma and lung cancer.

Among elderly patients, treating follicular lymphomas (FLs) results in better survival outcomes, a recent study has shown.

Researchers retrospectively assessed 3,705 elderly adults (aged 80 years; 60 percent female) diagnosed with FL between 2000 and 2013. Those treated according to existing guidelines were compared against those who received no treatment following propensity-score matching. Outcomes included overall survival time and 3-year restricted mean survival time (RMST).

Majority (68 percent; n=2,519) of the patients had received FL-directed therapy, initiated within a median of 61 days. Rituximab was the most common first-line agent. Seventy percent of the untreated participants died over a median follow-up of 2.2 years.

In the propensity score-matched cohorts, Kaplan-Meier curves revealed an overall median survival of 4.31 years in participants who received treatment. This was significantly greater than in the untreated group (median, 2.86 years; log-rank p<0.001).

Survival probabilities showed a similar trend. At each year following FL diagnosis, patients who received treatment showed better odds of survival than their untreated counterparts. The respective 3-year survival probabilities, for instance, were 0.61 and 0.48. The 5-year probabilities were 0.43 and 0.34, respectively.

Moreover, the 3-year RMST was 2.36 years for patients who had received treatment and only 2.05 years in those who had not.

Cox proportional-hazards models confirmed these findings: Treatment significantly reduced the likelihood of death by 23 percent (hazard ratio, 0.77, 95 percent confidence interval, 0.70–0.85).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 6 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
20 Sep 2020
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.